senolytic fda approval

What two therapies' approvals means for longevity science — Photo by Etatics Inc. on Pexels

Longevity Science Hits FDA Milestone: Venture Capital Alert?

Longevity Science Hits FDA Milestone: Venture Capital Alert? In 2026, the FDA approved its first senolytic therapy, prompting a $125 million Series C round for BlueCarbon Therapeutics and signaling a watershed for longevity biotech. This marks the first regulatory green light for drugs that clear aging cells, opening a clear